Search research articles
Contact Us
Filters
Showing results (431-440 of 459) with videos related to
Page
of 46
Sort By:
Journal of Medicinal Chemistry
|
April 20, 2018
Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors
Sharan K Bagal, Kiyoyuki Omoto, David C Blakemore, et al.
Micropublication Biology
|
November 29, 2022
Tubulin posttranslational modifications modify the atypical spermatozoon centriole
Katerina A Turner, Derek F Kluczynski, Ryan J Hefner, et al.
Nature
|
July 13, 2022
Retrograde movements determine effective stem cell numbers in the intestine
Maria Azkanaz, Bernat Corominas-Murtra, Saskia I J Ellenbroek, et al.
Science Signaling
|
October 2, 2014
Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt-β-catenin-mediated intestinal tumor growth and regeneration
Toby J Phesse, Michael Buchert, Emma Stuart, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
March 26, 2017
Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α
Priya Kishnani, Mark Tarnopolsky, Mark Roberts, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 15, 2017
Highly potent and selective Na<sub>V</sub>1.7 inhibitors for use as intravenous agents and chemical probes
R Ian Storer, Andy Pike, Nigel A Swain, et al.
Cancer Research
|
May 12, 2011
PHLDA1 expression marks the putative epithelial stem cells and contributes to intestinal tumorigenesis
Anuratha Sakthianandeswaren, Michael Christie, Carla D'Andreti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 31, 2024
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models
Sheryl M Gough, John J Flanagan, Jessica Teh, et al.
Nature Chemical Biology
|
June 16, 2015
Catalytic in vivo protein knockdown by small-molecule PROTACs
Daniel P Bondeson, Alina Mares, Ian E D Smith, et al.
Journal of Medicinal Chemistry
|
June 27, 2018
Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain
Sharan K Bagal, Mark Andrews, Bruce M Bechle, et al.
Page
of 46
Search research articles
Search
Showing results (431-440 of 459) with videos related to
Sort By:
Page
of 46
Journal of Medicinal Chemistry
|
April 20, 2018
Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors
Sharan K Bagal, Kiyoyuki Omoto, David C Blakemore, et al.
Micropublication Biology
|
November 29, 2022
Tubulin posttranslational modifications modify the atypical spermatozoon centriole
Katerina A Turner, Derek F Kluczynski, Ryan J Hefner, et al.
Nature
|
July 13, 2022
Retrograde movements determine effective stem cell numbers in the intestine
Maria Azkanaz, Bernat Corominas-Murtra, Saskia I J Ellenbroek, et al.
Science Signaling
|
October 2, 2014
Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt-β-catenin-mediated intestinal tumor growth and regeneration
Toby J Phesse, Michael Buchert, Emma Stuart, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
March 26, 2017
Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α
Priya Kishnani, Mark Tarnopolsky, Mark Roberts, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 15, 2017
Highly potent and selective Na<sub>V</sub>1.7 inhibitors for use as intravenous agents and chemical probes
R Ian Storer, Andy Pike, Nigel A Swain, et al.
Cancer Research
|
May 12, 2011
PHLDA1 expression marks the putative epithelial stem cells and contributes to intestinal tumorigenesis
Anuratha Sakthianandeswaren, Michael Christie, Carla D'Andreti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 31, 2024
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models
Sheryl M Gough, John J Flanagan, Jessica Teh, et al.
Nature Chemical Biology
|
June 16, 2015
Catalytic in vivo protein knockdown by small-molecule PROTACs
Daniel P Bondeson, Alina Mares, Ian E D Smith, et al.
Journal of Medicinal Chemistry
|
June 27, 2018
Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain
Sharan K Bagal, Mark Andrews, Bruce M Bechle, et al.
Page
of 46